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Background: Approximately 200,000 new cases of melanoma are diagnosed worldwide each year. Skin metastases
are a frequent event, occurring in 18.2% of cases. This can be distressing for the patient, as the number and size of
cutaneous lesions increases, often worsened by ulceration, bleeding and pain. Electrochemotherapy (ECT) is a local
modality for the treatment of cutaneous or subcutaneous tumors that allows delivery of low- and non-permeant
drugs into cells. ECT has been used in palliative management of metastatic melanoma to improve patients’ quality
of life. This is, to our knowledge, the first application of ECT as neoadjuvant treatment of metastatic subcutaneous
melanoma.
Methods and results: A 44-year-old Caucasian woman underwent extensive surgical resection of a melanoma,
with a Breslow thickness of 1.5 mm, located on the right side of her scalp. No further treatment was given and the
woman remained well until she came to our attention with a large nodule in her right cheek. Whole-body
fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) was performed for
staging and treatment monitoring. Baseline FDG PET/CT showed the lesion in the cheek to have a maximal
standardized uptake value (SUVmax) of 19.5 with no evidence of further disease spread. Fine needle aspiration
cytology confirmed the presence of metastatic melanoma. The patient underwent two sessions of ECT with
intravenous injections of bleomycin using a CliniporatorTM as neoadjuvant treatment permitting conservative
surgery three months later.
Follow-up PET/CT three months after the first ECT treatment showed a marked decrease in SUVmax to 5. Further
monitoring was performed through monthly PET/CT studies. Multiple cytology examinations showed necrotic
tissue. Conservative surgery was carried out three months after the second ECT. Reconstruction was easily achieved
through a rotation flap. Pathological examination of the specimen showed necrotic tissue without residual
melanoma. One year after the last ECT treatment, the patient was disease-free as determined by contrast-enhanced
CT and PET/-CT scans with a good functional and aesthetic result.
Conclusions: ECT represents a safe and effective therapeutic approach that is associated with clear benefits in
terms of quality of life (minimal discomfort, mild post-treatment pain and short duration of hospital stay) and may,
in the neoadjuvant setting as reported here, offer the option of more conservative surgery and an improved
cosmetic effect with complete local tumor control.
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Approximately 200,000 new cases of melanoma are diag-
nosed worldwide each year [1,2]. Skin metastases are a
frequent event, occurring in 18.2% of cases [3]. This can
be distressing for the patient, as the number and size of
cutaneous lesions increases, often worsened by ulcer-
ation, bleeding and pain. Electrochemotherapy (ECT) is
a local modality for the treatment of cutaneous or sub-
cutaneous metastases that allows delivery of low- and
non-permeant drugs into cells [4]. ECT has been used in
palliative management of metastatic melanoma to im-
prove patients’ quality of life [5-9]. This is, to our know-
ledge, the first application of ECT as neoadjuvant
treatment of metastatic subcutaneous melanoma.
Methods and results
A 44-year-old Caucasian woman underwent extensive
surgical resection of a melanoma, with a Breslow thick-
ness of 1.5 mm, located on the right side of her scalp.
No further treatment was given and the woman
remained well until she presented to our attention when
a large nodule appeared in her right cheek. Physical
examination revealed a 3.5 cm maximum diameter le-
sion partly adhered to the adjacent overlying skin but
with no apparent infiltration of the inner oral mucosa,
as confirmed by computed tomography (CT) scan. The
whole-body CT scan revealed a 3.5 cm maximum diam-
eter sandglass-shaped large mass, engaging the right
cheek, with the upper extremity close to the floor of the
orbit. No other metastatic localization was detected.
Whole-body fluorodeoxyglucose positron emission tom-
ography/CT (FDG PET/CT) was performed for staging
and treatment monitoring under standardized conditions
that included fasting for at least 6 h, administration ofFigure 1 Pre-treatment CT scan with evidence of sandglass-shaped m3.7 MBq/kg of FDG and imaging one hour after injec-
tion. The baseline FDG PET/CT study showed the lesion
in the cheek to have a maximal standardized uptake
value (SUVmax) of 19.5 with no evidence of further dis-
ease spread (Figure 1). Fine needle aspiration cytology
confirmed the presence of metastatic melanoma.
Standard radical surgery would have required a large
resection of the whole cheek, with wide safety margins
of the mass, including the skin and oral mucosa surface,
branches of the mandibolar facial nerve and part of the
orbit floor. Instead, the patient was spared this and
underwent two sessions of ECT using a CliniporatorTM
(IGEA S.p.A, Carpi, Italy) as elective treatment. The pa-
tient signed a detailed informed consent for the different
therapeutic options. ECT treatment was performed after
the approval of an appropriate ethics committee (IEC of
National Cancer Institute of Naples, reference number
273/10) in compliance with Helsinki Declaration, follow-
ing internationally recognized guidelines. The first
neoadjuvant ECT treatment was performed with the pa-
tient receiving intravenous (IV) bleomycin 15000 IU/m
[2] under general anesthesia. The second ECT session
was performed six weeks later with the same dose of
drug. In both treatments, the procedure was started 8
min after IV drug injection with linear configuration
needle electrodes (type II electrodes, length 20 mm,
4 mm distance between rows, IGEA S.p.A, Carpi, Italy)
being used. Twelve and 8 electric pulses were delivered
in the first and second ECT sessions, respectively. In
both, treatment was performed without dual application
on the same area so as to reduce the risk of necrosis. No
post-treatment complications and no peripheral nerves
injuries were observed. The first follow-up FDG PET/
CT scan was performed three months after the secondass of the right cheek and FDG-PET scan with a SUVmax of 19.5.
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the baseline scan and the SUVmax of the lesion had
decreased to 5. Further monitoring was performed
through monthly PET/CT. Multiple cytology examina-
tions showed necrotic tissue.
Conservative surgery was carried out three months
after the second ECT, and the mass excised, including a
narrow rim of healthy tissue margin and a small triangle
of adherent skin, sparing the inner layer, the oral mucosa
and the floor of the orbit. Reconstruction was easily
achieved through a rotation flap. Pathological examin-
ation of the specimen, which included a solid lesion with
a maximum diameter of 1.3 cm, showed necrotic tissue
without residual melanoma. Six months after surgery,
the SUVmax in the region of the lesion had further
decreased to 1.3 (Figure 2). One year after the last ECT,
the patient was disease-free as determined by CT and
PET/CT scans with a good functional and aesthetic re-
sult (Figure 3).
Discussion
Application of short and high-intensity electric pulses
(reversible electroporation) facilitates the intracellular
delivery of administered drugs. For example, the cyto-
toxic effect of bleomycin is increased by more than
8000-fold [10].
Electroporation of the cell membrane causes signifi-
cant vascular changes in the tumor region, inducing ar-
teriolar vasoconstriction with the reduction of tumorFigure 2 (Left) Post electrochemotherapy and (right) post surgical tre
and to 1,3.tissue blood perfusion (vascular lock). This effect
becomes irreversible when electric pulses are associated
with chemotherapy (vascular disrupting effect), leading
to an additional cascade. Tumor cell death, due to the
effect of bleomycin, is a result of long-term lack of oxy-
gen and nutrients and the accumulation of catalytic pro-
ducts. These effects also induce short-term cessation of
bleeding and the palliation of hemorrhaging and ulcer-
ated cutaneous lesions [11,12].
Currently, ECT indications include the local control of
single and in-transit metastatic melanoma skin nodules not
amenable to surgery or isolated limb perfusion or infusion,
non-melanoma skin cancer, local recurrences and skin me-
tastases from breast cancer, skin metastases from head and
neck cancer and local recurrences in the oral cavity [13-19].
Since the first clinical experience of Mir et al. (1991) [20], a
number of studies have shown that ECT is associated with
a good overall response rate (92-99%), with a complete re-
sponse rate of between 53% and 89%, without serious nega-
tive adverse events [6,7,21,22]. Quaglino et al. (2008)
reported an overall response rate in 93% of patients with
cutaneous metastases and improved local tumor control
with repeated ECT. Moreover, in metastases >1 cm [2]
which had lower response rates after the first ECT, a good
antitumor effect was observed after retreatment with a
complete response rate for 87% of the treated lesions after
multiple ECT sessions [6]. Another advantage of ECT is the
possibility to treat wider areas than the targeted metastatic
lesion region, in order to avoid locoregional relapse. Inatment FDG-PET scan with SUVmax respectively decreased to 5
Figure 3 Pre–treatment clinical image and post-operative image with a good functional and aesthetic result.
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single metastatic nodule can improve local tumor control
as demonstrated in patients with long-lasting response [23].
In the local control of cutaneous and subcutaneous
metastatic lesions, ECT overcomes the low efficacy of
classical chemotherapy and may mean surgery can be
avoided. However, to our knowledge, its use has never
previously been described in a neoadjuvant fashion to
reduce the surgical extension in patients with metastatic
melanoma.
Interestingly, ECT has been employed as a tissue-sparing
treatment to reduce tumor burden for further treatments
and surgery in other tumor types. One report described the
use of preoperative ECT of anal melanoma to enable surgi-
cal resection with organ and function-sparing effect while a
second case described ECT of a digital chondrosarcoma to
avoid finger amputation [24,25]. In both cases, ECT
appeared to be an effective neoadjuvant treatment for
maintaining organ function and reducing the extent of sur-
gical intervention. The favorable outcome of using neoadju-
vant ECT for a metastatic melanoma nodule in the case
presented here was evident as early as three weeks after the
first session, with an 18-FDG PET-CT scan revealing a
rapid four-fold decline in biological tumor activity from the
baseline assessment as measured by SUVmax. Conservative
surgery was carried out three months after the second ECT
session and, to date, the patient remains disease-free with
good functional and aesthetic outcomes (Figure 3). ECT
was safely repeated on the basis of the positive response
obtained after the first session. Moreover, as a consequence
of the bleomycin mitotic cell death process, ECT was ef-
fectively targeted towards cancer cells, sparing adjacent
healthy tissue of the cheek. ECT can therefore be applied to
improve the patient’s quality of life, independent of life ex-
pectancy, to heal painful or bleeding lesions and also to pre-
serve patients’ appearance and social interactions. A
systematic review by Kis et al. (2011) similarly concluded
that ECT in cutaneous melanoma is easy to perform with-
out the potentially undesirable side effects of systemicchemotherapy and does not cause significant organ dys-
function or permanent disfigurement [19].
Conclusions
ECT represents a safe and effective therapeutic approach
that is associated with clear benefits in terms of quality
of life (minimal discomfort, mild post-treatment pain
and short duration of hospital stay) and may, in the
neoadjuvant setting as reported here, offer the option of
more conservative surgery and an improved cosmetic ef-
fect with complete local tumor control.
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